Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects

"Dose escalating cohort driven study. 6 planned cohorts.~1. HE3286 5 mg or placebo QD for 28 days;~2. HE3286 10 mg (5 mg BID) or placebo BID for 28 days~3. HE3286 20 mg (10 mg BID) or placebo BID for 28 days~4. HE3286 40 mg (20 mg BID) or placebo BID for 28 days~5. HE3286 4 mg (2 mg BID), 20 mg (10 mg BID) or placebo BID for 28 days~6. HE3286 10mg (5 mg BID) for 28 days (open-label cohort in patients with T2DM)"